Drug profile · INN
gemfibrozil
LOPID
gemfibrozil (LOPID) is a peroxisome proliferator-activated receptor alpha agonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Drug details — gemfibrozil
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 6
- Programs
- 25
- Data quality
- 0.89
Quick answer
gemfibrozil (LOPID) is a peroxisome proliferator-activated receptor alpha agonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Peroxisome proliferator-activated receptor alpha agonist
Primary target: Peroxisome proliferator-activated receptor alpha
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Related patents
-
US 11642335
Chemical synthesis of clopidogrel active metabolites and disulfide conjugate prodrugs
granted -
US 9889125
Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy
granted -
US 9233103
Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy
granted -
US 7259261
Racemization and enantiomer separation of clopidogrel
granted -
US 6800759
Racemization and enantiomer separation of clopidogrel
expired -
US 6737411
Racemization and enantiomer separation of clopidogrel
expired
Frequently asked questions
What is gemfibrozil?
gemfibrozil (LOPID) is a peroxisome proliferator-activated receptor alpha agonist. Associated with Teva Pharma GmbH. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for gemfibrozil?
LOPID is a marketed brand name for gemfibrozil. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of gemfibrozil?
gemfibrozil has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.